Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ced 2008 mipomersen development plan with Genzyme

-- Reported preclinical study in Circulation showing that mipomersen

lowers Lp(a) and oxidized-LDL, independent risk factors for

cardiovascular disease

-- Initiated Phase 3 study in heterozygous FH subjects with coronary

artery disease

-- Granted broad patent coverage for antisense compounds targeting

apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense

modulation of Apolipoprotein B Expression"

Metabolic Program

-- Highlighted our robust diabetes and obesity portfolio with nine

presentations and posters at the American Diabetes Association meeting

-- Presented new preclinical data relating to ISIS 388626, Isis' drug

targeting SGLT2

-- Presented results from eight research programs on novel targets

that offer new mechanisms to address metabolic diseases, including

obesity

Other Partnered Programs

-- ATL and Teva reported encouraging Phase 2 results for ATL/TV1102,

targeting VLA-4 in patients with multiple sclerosis

-- Partnered oncology drugs highlighted at the American Society of

Clinical Oncology demonstrate the potential of antisense technology to

treat multiple cancers

-- OncoGenex reported encouraging Phase 2 results on OGX-011,

targeting clusterin, in patients with hormone refractory prostate

cancer

-- Eli Lilly and Company reported positive Phase 1 clinical trial

results for LY2181308, targeting survivin

-- Atlantic Healthcare received U.S. orphan drug designation for

alicaforsen for the treatment of pouchitis

-- Altair Therapeutics advanced AIR 645 into Phase 1 studies for the

treatment of asthma

Regulus Therapeutics (microRNA Joint Venture)

-- Entered into strategic alliance wit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... The " Anesthesia Drugs Market (2011 ... studies the U.S. market for intravenous anesthesia drugs with special focus on ... import system for controlled substances in U.S. and U.S. market entry strategy. ...   " Anesthesia Drugs Market (2011 - ...
... was able to reach for and sip from a drink on ... by using her thoughts to direct a robotic arm. ... is evaluating the safety and feasibility of an investigational device called ... brain-computer interface (BCI) intended to put robotics and other assistive technology ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) announced ... Company,s common share repurchase program authorization by an additional ... 2008, the Company has returned $236 million to shareholders ... preferred shares, representing approximately 27% of its shares as ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/20/2014)... breast and pancreatic cancers also promote drug-resistance and ultimately ... San Diego School of Medicine have discovered a molecule, ... tumors that appears responsible for inducing tumor metastasis by ... , The findings, published in the April 20, 2014 ... point to new therapeutic opportunities for reversing drug resistance ...
(Date:4/20/2014)... -- Using corn crop residue to make ethanol and ... greenhouse gases than gasoline, according to a study published ... , The findings by a University of Nebraska-Lincoln team ... be used to meet federal mandates to ramp up ... stover -- the stalks, leaves and cobs in cornfields ...
(Date:4/18/2014)... population predicted to reach 9 billion by 2050 ... considers human-altered landscapes such as farmland, according to ... that supports it might be an increasingly scarce ... of the land surface is directly affected by ... impacts such as climate change. But what if ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... of biodiversity, but there has been no effective way ... areas. As a result, we have limited understanding of ... are affecting these delicate ecosystems. A major advance in ... Asner of the Carnegie Institution,s Department of Global Ecology ...
... 2008) With the sequencing of the human genome ... a genes and other DNA sequences can vary widely between ... our species, genetic diversity but it has also been linked ... Harbor Protocols ( www.cshprotocols.org/TOCs/toc6_08.dtl ) features a new method ...
... the human malaria parasite, Plasmodium falciparum, which is responsible ... from becoming sexually mature. The discovery ... resistance, which is a major public health problem and ... cycle of Plasmodium falciparum is complex, and it is ...
Cached Biology News:Revolution in rain forest monitoring with MacArthur grant 2Cold Spring Harbor Protocols features methods for analyzing genomes and plant cells 2
... are designed to rapidly and reliably ... our patented APA Technology. APAgene provides ... extraordinarily competitive price. All necessary ingredients ... Locator Kit can be used for ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... system automates the denaturation and hybridization steps ... convenience for clinical and research personnel. The ... of sample types, is easy to use, ... 50% while ensuring overall precision and accuracy ...
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
Biology Products: